Complementary/alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology

Breast Journal

Volumn 12, Issue 6, 2006, Pages 526-530

  Ernst, Edzard ^a   Schmidt, Katja ^a   Baum, Michael ^b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b Portland Hospital   (United Kingdom)

Author keywords

Alternative cancer cures; Alternative medicine; Breast cancer; Complementary medicine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FACTOR AF2; INTERLEUKIN 2; MELATONIN; SHI QUAN DA BU TANG; THYMOSTIMULIN; TRANSFER FACTOR;

ALTERNATIVE MEDICINE; ARTICLE; BEHAVIOR THERAPY; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE COURSE; FAMILY THERAPY; GROUP THERAPY; HUMAN; HYPNOSIS; MEDICAL LITERATURE; MEDITATION; METHODOLOGY; MUSCLE RELAXATION; MUSCLE TRAINING; NOMENCLATURE; PEER COUNSELING; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QUALITY CONTROL; SCORING SYSTEM; SOCIAL SUPPORT; SUPPORT GROUP; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TERMINOLOGY;

EID: 33750626364     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2006.00340.x     Document Type: Article

References (25)

1. DiGianni LM, Kim HT, Emmons K, Gelman R, Kalkbrenner KJ, Garber JE. Complementary medicine use among women enrolled in a generic testing programme. Cancer Epidemiol Biomarkers Prev 2003;12:321-6.
2. Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 2004;22:671-7.
3. Henderson JW, Donatelle RJ. Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 2004;10:52-7.
4. World Health Organization CAM definition. http://www.who.int/medicines/ organization/trm/orgtrmmain.shtml (accessed on 16 April 2004).
5. Cochrane Complementary Medicine Field CAM definition. http://www.compmed.umm.edu/compmed/cochrane/cochrane.htm (accessed on 16 April 2004).
6. American Cancer Society CAM definition. Developed by the ACS Advisory Group on Complementary and Alternative Methods and reviewed by the ACS Medical Affairs Committee August 12, 1999. http://www.cancer.org/docroot/ETO/content/ ETO_5_1_Introduction.asp (accessed on 16 April 2004).
7. Clarke M, Oxman AD, eds. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. In: The Cochrane Library, Issue 2. Oxford: Update Software, 2003.
8. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
9. Smith LA, Oldman AD, McQuay HJ, Moore RA. Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain 2000;86:119-32.
10. Rainer H, Moser K, Bettelheim P. Randomised study: chemotherapy versus chemotherapy plus transfer factor in metastasised breast neoplasm. Verh Dtsch Ges Inn Med 1978;84:604-6.
11. Morgenstern H, Gellert GA, Walter SD, Ostfeld AM, Siegel BS. The impact of a psychosocial support program on survival with breast cancer: the importance of selection bias in program evaluation. J Chronic Dis 1984;37:273-82.
12. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;8668:888-91.
13. Adachi I. Supporting therapy with Shi Quan Da Bu Tang in advanced breast cancer patients. Biomed Res 1990;11(Suppl.):25-32.
14. Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol 1993;11:66-9.
15. Pavesi L, Italian Co-operative Trials Group. Fluoracell (F), with and without high-dose folinic acid (HDFA) plus epirubicin (E) and cyclophosphamide (C): FEC versus HDFA-FEC plus or minus thymostimulin (TS) in metastatic breast cancer: results of a multicentre study. Eur J Cancer, 1993;29(Suppl. 6):S77.
16. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994;69:196-9.
17. Ilnyckyj A, Farber J, Cheang MC, Weinerman BH. A randomised controlled trial of psychotherapeutic intervention in cancer patients. Ann RCPSC 1994;27:93-6.
18. Cunningham AJ, Edmonds CV, Jenkins GP, Pollack H, Lockwood GA, Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology 1998;7:508-17.
19. Edelman S, Lemon J, Bell DR, Kidman AD. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 1999;8:474-81.
20. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688-92.
21. Walker LG, Walker MB, Ogston K, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999;80:262-8.
22. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001;345:1719-26.
23. Kissane DW, Love A, Hatton A, et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol 2004;22:4255-60.
24. Ost B. Remissionserhaltung nicht-metastasierter Mammakarzinome unter Faktor AF2. Dtsch Z Onkol 1989;21:102-4.
25. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115.